Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 453 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Progesterone Clear all
Recruiting Phase 4 Interventional Accepts healthy volunteers

Progesterone Preeclampsia

NCT07448597
View directory record Official record
Conditions
Preeclampsia, Hypertensive Disorder of Pregnancy
Interventions
Progesterone supplementation
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Female only
Enrollment
642 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 19, 2026, 6:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

HSG and Tubal Patency Study

NCT02146248
View directory record Official record
Conditions
Tubal Patency
Interventions
combined oral contraceptive, DepoProvera
Drug
Lead sponsor
Jeffrey Jensen
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 19, 2026, 6:32 PM EDT
Active, not recruiting Phase 3 Interventional

Estrogen Administration for the Treatment of NASH in Postmenopausal Women

NCT04833140
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Estradiol patch, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 19, 2026, 6:32 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study

NCT00958412
View directory record Official record
Conditions
Endometriosis
Interventions
Proellex®
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
8
States / cities
Tucson, Arizona • San Diego, California • San Ramon, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 19, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available

Pregnenolone and Marijuana Dependence

NCT02439814
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Pregnenolone, Placebo
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 19, 2026, 6:32 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives

NCT01750476
View directory record Official record
Conditions
Initiation of Oral Contraception (OC), Initiation of Depo-Provera (DMPA), Initiation of Mirena (LNG-IUD)
Interventions
Mirena, Oral contraception, Depo-Provera
Drug
Lead sponsor
Thomas Cherpes, DVM, MD
Other
Eligibility
15 Years to 25 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Oct 19, 2026, 6:32 PM EDT
Withdrawn No phase listed Observational

Breast Cancer BRCA1 Carriers: a Pilot Study

NCT05062174
View directory record Official record
Conditions
BRCA1 Mutation, High-grade Serous Ovarian Cancer, TNBC - Triple-Negative Breast Cancer
Interventions
Mifepristone 200 MG, Prophylactic mastectomy
Drug · Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Oct 19, 2026, 6:32 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Progesterone in Gender Affirming Hormone Therapy Study

NCT06807580
View directory record Official record
Conditions
Transgender Women
Interventions
Placebo, Progesterone
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 19, 2026, 6:32 PM EDT
Not listed Phase 2 Interventional

Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA

NCT02064725
View directory record Official record
Conditions
Recurrent or Persistent Endometrial Carcinoma
Interventions
Sodium cridanimod
Drug
Lead sponsor
Kevelt AS
Industry
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
San Jose, California • Santa Rosa, California • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 19, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility

NCT03401918
View directory record Official record
Conditions
Recurrent Pregnancy Loss, Unexplained Infertility
Interventions
Uterine ERA and microbiome testing, Oral antibiotics and vaginal probiotics
Diagnostic Test · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 19, 2026, 6:32 PM EDT
Withdrawn Phase 2 Interventional

SIRT-1 Antagonism for Endometrial Receptivity

NCT04184323
View directory record Official record
Conditions
Endometriosis, Uterine Diseases, Endometrial Diseases, Infertility Unexplained, Infertility; Female, Nonimplantation
Interventions
EX-527 (Selisistat), Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 19, 2026, 6:32 PM EDT
Completed Phase 4 Interventional Results available

Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders

NCT02582905
View directory record Official record
Conditions
Alcohol Use Disorder, Bipolar Disorder, Schizoaffective Disorder Bipolar Type
Interventions
Placebo, Citicoline, Pregnenolone
Drug · Dietary Supplement
Lead sponsor
Sherwood Brown, MD, PhD
Other
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
Miami, Florida • Dallas, Texas • Edinburg, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 19, 2026, 6:32 PM EDT
Completed Phase 1 Interventional

Sex Differences in Progesterone Effects on Responses to Stress and Drug Cues

NCT00585520
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Progesterone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Oct 19, 2026, 6:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood

NCT02509767
View directory record Official record
Conditions
Contraception
Interventions
Subcutaneous depot medroxyprogesterone acetate
Drug
Lead sponsor
Planned Parenthood Federation of America
Other
Eligibility
15 Years to 44 Years · Female only
Enrollment
401 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Morristown, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 19, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available

Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors

NCT01831076
View directory record Official record
Conditions
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions
Exemestane, Exemestane and tamoxifen
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 19, 2026, 6:32 PM EDT
Terminated Early Phase 1 Interventional

Natural Progesterone for the Treatment of Recurrent Glioblastoma

NCT05091866
View directory record Official record
Conditions
Gliosarcoma, Recurrent Glioblastoma
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Progesterone
Other · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 19, 2026, 6:32 PM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Vaginal Progesterone in Twins With Short Cervix

NCT01812239
View directory record Official record
Conditions
Premature Birth
Interventions
Vaginal Progesterone gel., fetal fibronectin swab., Placebo gel
Drug · Procedure
Lead sponsor
Obstetrix Medical Group
Industry
Eligibility
18 Years to 60 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 19, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available

Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer

NCT00338728
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, KIT Positive, PDGFR Positive, Postmenopausal, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Imatinib Mesylate, Letrozole
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 19, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available

Neurobiology of Bulimia Nervosa

NCT04225221
View directory record Official record
Conditions
Bulimia Nervosa
Interventions
Estradiol, Micronized progesterone, Leuprolide Acetate, Placebo Oral Capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 19, 2026, 6:32 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Mifepristone Induction for Fetal Demise

NCT02620904
View directory record Official record
Conditions
Intrauterine Fetal Demise, Fetal Death
Interventions
Mifepristone, placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
16 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 19, 2026, 6:32 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Pregnenolone for Cannabis Use Disorder and Depression

NCT07685964
View directory record Official record
Conditions
Cannabis Use Disorder, Major Depressive Disorder (MDD)
Interventions
Pregnenolone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 19, 2026, 6:32 PM EDT
Not listed Not applicable Interventional

Frozen Blastocyst Transfer Using Conventional Timing Versus Timing by Endometrial Receptivity Analysis

NCT03558399
View directory record Official record
Conditions
Implantation Failure, Infertility, Female
Interventions
FET according to ERA, FET according to standard protocol
Other
Lead sponsor
Shady Grove Fertility Reproductive Science Center
Other
Eligibility
30 Years to 40 Years · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 19, 2026, 6:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Continuation of Subcutaneous and Intramuscular Depot Medroxyprogesterone Acetate in Post-abortion Patients

NCT05505435
View directory record Official record
Conditions
Contraception
Interventions
Depot-Medroxyprogestereone Acetate
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 19, 2026, 6:32 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Assessment of Day-night Secretion of Progesterone and LH Across Puberty

NCT02155933
View directory record Official record
Conditions
Puberty, Hyperandrogenism
Interventions
Blood sampling
Other
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 17 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 19, 2026, 6:32 PM EDT